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Abstract: Enteroviruses are ubiquitous mammalian pathogens that can produce mild to life-
threatening disease. We developed a multimodal, rapid, accurate and economical point-of-care
biosensor that can detect nucleic acid sequences conserved amongst 96% of all known enteroviruses.
The biosensor harnesses the physicochemical properties of gold nanoparticles and oligonucleotides
to provide colourimetric, spectroscopic and lateral flow-based identification of an exclusive enterovi-
ral nucleic acid sequence (23 bases), which was identified through in silico screening. Oligonu-
cleotides were designed to demonstrate specific complementarity towards the target enteroviral
nucleic acid to produce aggregated gold–oligonucleotide nanoconstructs. The conserved target
enteroviral nucleic acid sequence (≥1 × 10−7 M, ≥1.4 × 10−14 g/mL) initiates gold–oligonucleotide
nanoconstruct disaggregation and a signal transduction mechanism, producing a colourimetric and
spectroscopic blueshift (544 nm (purple) > 524 nm (red)). Furthermore, lateral-flow assays that
utilise gold–oligonucleotide nanoconstructs were unaffected by contaminating human genomic
DNA, demonstrated rapid detection of conserved target enteroviral nucleic acid sequence (<60 s),
and could be interpreted with a bespoke software and hardware electronic interface. We anticipate
that our methodology will translate in silico screening of nucleic acid databases to a tangible en-
teroviral desktop detector, which could be readily translated to related organisms. This will pave the
way forward in the clinical evaluation of disease and complement existing strategies to overcome
antimicrobial resistance.
Keywords: gold nanoparticles; oligonucleotides; gold–oligonucleotide nanoconstructs; lateral flow
assay; enterovirus; virus; nucleic acid sequences; UV–Vis; multiplexing; multimodal; variant
detection; spectroscopy; point-of-care
1. Introduction
Enteroviruses are mammalian pathogens that are transmitted either through the
gastrointestinal or respiratory pathways. More than 100 different enteroviruses have been
identified, and new pathogenic strains are being discovered because of their high mutation
and recombination rates [1].
The enterovirus genus currently consists of 15 species (Enterovirus A-L and Rhi-
novirus A-C) [1], with potentially new species still being identified [2,3]. These species
are associated with mild and serious disease [4], which include the common cold [5] and
poliomyelitis [6], respectively. Furthermore, because of symptom similarities, patient pres-
sure, and fear of inaccurate clinical evaluation, enterovirus infections are often evaluated
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as serious bacterial infections. Bacterial infections, unlike enteroviral infections, can be
effectively treated with antibiotics [7]; however, if they are left untreated, they can ulti-
mately become life-threatening [8]. As a result, antibiotics are overprescribed [9] and have
contributed to the rise of antimicrobial resistance, which is associated with both long-term
medical and economic uncertainty [10]. Therefore, an improved understanding of infec-
tious organisms [11] and their detection [12] could enhance therapeutics that effectively
cure and alleviate the symptoms of disease.
At present, conventional enterovirus detection instruments, such as electron [13],
light, and fluorescence microscopy [14], and methods, such as polymerase chain reaction
(PCR) [15] and microtiter plate-based enzyme-linked immunosorbent assay (ELISA) [16],
are not always practical in clinical settings. This is because traditional instruments and
methods are often uneconomical, require extensive training to correctly operate, and are
time-consuming, such that they do not meet the requirements of a typical doctor–patient
consultation (~10 min) [17]. Microtiter-based ELISA has demonstrated breakthroughs in
the field through the detection of viruses [18] and has been advanced for clinical settings
through the development of lateral flow assays [19], which prove to be economical, simple,
and rapid [20,21]. Excellent examples of cases in which ELISA-based lateral flow assays are
widely implemented include the ubiquitous pregnancy test [22] and more recently SARS-
CoV-2 [23]. However, ELISA, which utilises antibodies to detect analytes of interest, is
restricted by its potential to detect small molecular weight targets and variable biosynthesis
methods [24]. Consequently, efforts have been directed towards the development of rapid,
accurate, and economical point-of-care biosensors that capitalise on innovative detection
mechanisms that could be used to stratify individuals presenting with the symptoms of
viral infections.
Oligonucleotide biosensors [25], such as aptamer-based biosensors [26], are an ex-
ample of an emerging technology that is beginning to rival existing infection detection
systems [27]. This is due to their economical manufacture, ease of production, high stability,
and ability to effectively bind targets with high affinity and specificity [28]. Oligonu-
cleotides have been designed to detect an array of biochemically diverse targets, which
include low molecular weight compounds [29], proteins [30], nucleic acids [31], bacte-
ria [32], and eukaryotic cells [33]. Furthermore, a number of innovative signal transduction
mechanisms have been developed to detect analytical targets [34], which include quan-
tification of fluorescence emission from quantum dot encoding of oligonucleotide-linked
nanostructures [35], electrochemical biosensing using oligonucleotide functionalised plat-
inum nanoparticles [36], and magnetic resonance imaging of oligonucleotide functionalised
superparamagnetic iron oxide nanoparticles [37]. Sophisticated methods that combine de-
tection modalities, including fluorescence anisotropy and electrochemical detection, [38] of
viral particles with ultra-high sensitivities have also been explored.
Oligonucleotides that utilise the spectroscopic properties of gold nanoparticles [39,40]
as they transition from aggregated and disaggregated states as a signal transduction mech-
anism for colourimetric [41] or lateral flow assays [42], have demonstrated enhanced
utility and clinical practicality in detecting biochemical markers, such as adenosine and
cocaine [43], thrombin [44], ATP [45], and platelet-derived growth factor receptors [46].
Therefore, oligonucleotides specific to viral biomarkers [47] and gold nanoparticles engi-
neered to change their aggregation state when exposed to a target could be used to stratify
patients infected with enteroviruses to improve disease management, augment treatment
pathways, and prevent the rise of antimicrobial resistance [48].
In this article, we describe the development of a multimodal gold–oligonucleotide
nanoconstruct-based biosensor composed of gold nanoparticles and an in silico designed
oligonucleotide sequence that can determine the presence of a target nucleic acid sequence,
which is conserved amongst all known enteroviruses, by demonstrating a colourimetric
change that can be detected spectroscopically or through the use of lateral flow. Gold
nanoparticles were synthesised by sodium citrate reduction. The conserved enteroviral se-
quence was identified through alignment of archetypal enteroviral nucleic acid sequences,
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from which a specific and complementary oligonucleotide sequence was engineered. Gold–
oligonucleotide nanoconstructs were characterised using dynamic light scattering (DLS),
transmission electron microscopy (TEM), and ultra-violet spectrophotometric analyses. Lat-
eral flow assays were fabricated through deposition of a streptavidin band on a membrane
that can capture dissociated gold nanoparticles functionalised with biotinylated nucleic
acid in the presence of a conserved target enteroviral nucleic acid sequence.
2. Materials and Methods
2.1. Materials
Gold (III) chloride hydrate, sodium citrate trisodium salt, sodium acetate trihydrate,
glacial acetic acid Trizma® acetate, sodium chloride, sodium hydroxide, tris(2-carboxyethyl)
phosphine hydrochloride, and phosphate buffered saline, were purchased from Sigma
Aldrich (Gillingham, UK). A human genomic DNA control was obtained from BioLine
(London, UK). Ultra-pure water (18.2 MΩ.cm) was generated by Elga PureLab Ultra 2
(ULXXXGEM2) and DNase & RNase free water was obtained from Gibco (Life Technolo-
gies, Loughborough, UK). Oligonucleotide sequences were obtained from Eurogentec
(Liège, Belgium). The STM discovery board (STM32F407G-DISC1), Vero board, Kingbright
(L-493GT Green LED), LittelFuse (500 mA), AC/DC power supply, straight pin header
(2.54 mm Pitch 3 way, 1 row), LDO regulator (LM2940CT-5.0/NOPB), multilayer ceramic
capacitor (KEMET 100 nF), aluminium electrolytic capacitor 100 µF (Panasonic), radial
T leaded PCB mount fuse (LittelFuse 500 mA), pitch 50 way 2 row straight PCB socket
(Through Hole, Stelvio Kontek MINICOM Series, 2.54 mm), right angle through hole
DC power socket (Wurth Elektronik WR-DC series, 5.5 mm, 160 × 90 × 50 mm), trim-
mer resistor with pin terminations (100 kΩ, Bourns 3296W Series, 25-Turn), turn through
hole trimmer resistor with pin terminations (20 kΩ, Vishay 64 W Series 19 (Electrical),
22 (Mechanical)), and ABS enclosure (IP66, 160 × 90 × 60.5 mm) were acquired from
RS Components.
2.2. Methods
2.2.1. Synthesis of Gold Nanoparticles
Gold chloride (0.017 g) was dissolved in deionised water (0.001 M, 50 mL) and heated
under reflux. A solution of sodium citrate tribasic in deionised water (0.039 M, 5 mL) was
prepared and added to the reaction mixture with continuous stirring for a further 20 min
under reflux. The mixture was cooled to room temperature and stored under refrigeration
(2–8 ◦C).
2.2.2. Synthesis of Gold–Oligonucleotide Nanoconstructs
First, gold nanoparticles were functionalised by linking thiolated nucleic acid to
gold nanoparticle surfaces and aggregated through hybridisation of a sensory oligonu-
cleotide strand. The sensory oligonucleotide strand was hybridised by two different
complementary nucleic acid strands, such that SH-Sequence-A and SH-Sequence-B-Biotin
were complementary to the 3′ and 5′ ends of the oligonucleotide, respectively. To prepare
gold–oligonucleotide nanoconstructs that utilise the signal transduction mechanism of
a lateral flow assay, a mixture of SH-Sequence-A and SH-Sequence-B-Biotin was used in a
1:1 ratio. The biotin-functionalised nucleic acid gold constructs bind membranes doped
with streptavidin at predefined locations.
Methods for the formation of gold–oligonucleotide nanoparticle constructs were
adapted from a previous study reported by Liu and Lu [49]. Briefly, Sequence-A (9 µL,
1 mM) and a mixture of Sequence-A (4.5 µL, 1 mM) and Sequence-B-Biotin (4.5 µL, 1 mM)
were added to two separate sodium hydroxide (12 M)-cleaned vials. Tris(2-carboxyethyl)
phosphine (TCEP, 1.5 µL, 10 mM) and acetate buffer (pH 5.2, 1 µL, 500 mM) were added
to each vial and incubated at room temperature for 1 hr. Gold nanoparticle suspensions
(3 mL) were added to each vial and stirred overnight. Tris acetate buffer (pH 8.2, 30 µL
500 mM) and sodium chloride solution (300 µL, 1 M) were added dropwise to each vial
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and stirred overnight. Functionalised gold nanoparticle suspensions were transferred to
micro-centrifuge tubes and washed with sodium chloride (100 mM)/Tris acetate (25 mM)
solution and centrifuged (1 mL, 3 times, 16,110 g, 15 min), discarding the supernatant
after each wash. After the final wash, the contents of the vials containing gold nanopar-
ticles conjugated to Sequence-A and a mixture of Sequence-B and Sequence-B-Biotin were
combined in a single vial suspended in sodium chloride (300 mM)/Tris acetate (25 mM)
buffer solution (1 mL). To this vial, the sensory oligonucleotide strand was added (60 µL,
10 µM) to hybridise with oligonucleotide-functionalised gold and allowed to aggregate
overnight under refrigeration (4 ◦C). The following day the aggregated nanoparticles
were washed with sodium chloride (600 mM)/Tris acetate (25 mM) buffer solution and
centrifuged (1 mL, 3 times, 800 g, 2 min) to eliminate free sensory oligonucleotide. When
the detection limit was 1 × 10−7 M and the ratio of target conserved enteroviral nucleic
acid to oligonucleotide to Sequence-A, Sequence-B, and Sequence-B-Biotin was 1:1:0.5:0.5, in a
1 mL sample of concentrated gold–oligonucleotide nanoconstructs, the amount of nucleic
acid bound to gold nanoparticle surfaces was estimated to be 0.1 nmol for Sequence-A and
0.05 nmol for Sequence-B and Sequence-B-Biotin. The final pellet was suspended in sodium
chloride (600 mM)/Tris acetate (25 mM) buffer solution (3 mL) and was ready to use for
experimentation or stored under refrigeration (4 ◦C).
2.2.3. Dynamic Light Scattering (DLS)
Dynamic light scattering was performed using a Malvern Zetasizer Nano ZS. The
system was equipped with a 5 mW He-Ne laser source (633 nm), operating at an angle of
173◦. Measurements (42 runs, 25 ◦C) were made using a disposable Sarstedt® polystyrene
cuvette. The mean hydrodynamic diameter of the particles was computed from the intensity
of the scattered light using Malvern Zetasizer software (6.12). All measurements were
conducted in triplicate.
2.2.4. Transmission Electron Microscopy
A suspension of gold nanoparticles was deposited onto a Formvar (3.05 mm) carbon
support TEM copper grid and allowed to settle (5 min). Excess nanoparticle suspension was
drawn away using filter paper (Whatman, grade 1:11 µm). The particles were imaged using
an FEI Tecnai 12 Biotwin TEM (100 kV). All measurements were conducted in triplicate.
2.2.5. Zetasizer
Nanoparticle suspensions were transferred to zetasizer cuvettes (DTS1061, Malvern)
and flushed with filtered deionised water. Zeta potential measurements were made in
triplicate for nanoparticle suspensions in deionised water and PBS (0.001 M) (parameters
used for dispersant deionised water dispersant: refractive index, 1.330; viscosity, 0.8872 cP;
dielectric constant, 78.5 εr; Model Smoluchowski F (Ka), 1.5). All samples were equilibrated
to 25 ◦C for 120 s prior to measurement. All measurements were conducted in triplicate.
2.2.6. Ultraviolet Spectrophotometry
Determination of the sensitivity of the biosensor to a conserved target enteroviral
nucleic acid sequence was recorded using both changes in absorbance intensity and wave-
length shift using a Tecan (Spark 10 M) plate-reading spectrophotometer. The sensitivity
was determined by producing log10 dilutions of conserved target enteroviral nucleic acid
sequence, from 200 µM to 2 pM, followed by the addition of equal volumes of gold–
oligonucleotide nanoconstructs to produce a final concentration range from 1 × 10−3 M to
1 × 10−14 M. All measurements were conducted in triplicate.
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2.2.7. Lateral Flow Assay
Lateral flow devices were prepared through assembly of cellulose fibre sample pads
(1 cm × 1 cm, Millipore) for solvent absorption and wicking, glass fibre conjugation pads
(1 cm × 1 cm, Millipore) for sample deposition, and a HiFlow Plus membrane (1 cm/4 cm,
90 s/4 cm, Millipore) on the surface of adhesive laminated printing paper (see supporting
information, Figures S1 and S2). A streptavidin suspension (10 mg/mL) was deposited
halfway up the lateral flow membrane to capture disaggregated gold nanoparticles function-
alised with Sequence-B. A sample of test solution (20 µL) containing gold–oligonucleotide
nanoconstructs and a test sample of target enteroviral sequence were deposited on the sam-
ple pad of the lateral flow test strips, which were placed in 1 mL of running buffer composed
of sodium chloride (600 mM) and tris acetate (25 mM) in deionised water (18.2 MΩ.cm). Lat-
eral flow operation is demonstrated in Supporting Movie S1 (Supplementary Materials).
2.2.8. Cross-Sensitivity/ Selectivity Analyses
To determine whether the gold–oligonucleotide nanoconstructs were able to detect the
conserved target enteroviral nucleic acid sequence from simulated mucosal environments,
cross-sensitivity analyses were conducted by doping test samples with mass equivalent
human genomic DNA (6.15 × 10−12 M) prior to biosensor assessment. Cross-sensitivity-
analyses were conducted at the detection limit of the conserved target enteroviral nucleic
acid sequence of 1 × 10−7 M. The efficacy of the gold–oligonucleotide nanoconstructs
in the presence of human genomic DNA was conducted in the absence and presence of
conserved target enteroviral nucleic acid sequence and assessed via lateral flow assay.
2.2.9. Electronic Desktop Detection
Electronic discrimination of the lateral flow detection band was conducted by monitor-
ing the change in electrical resistance across a light-dependent resistor (LDR) as a function
of the amount of light reflected from the surface of the lateral flow membrane. The change
in resistance was interpreted on a 12-bit scale (0–4095 au) using a microcontroller (STM
discovery) board. The microcontroller board was programmed using Keil (µVision5) so
that if resistance fell below or above a predetermined threshold because of a reduction in
light reflectance in the presence of a positive detection band, an electronic user interface
would read a “POSITIVE” or “NEGATIVE” message. The threshold (2118 au) was set at
the output value of the limit of detection for a lateral flow test membrane plus three times
the standard deviation (SD) of the noise (2163 au ± 15 SD au). For further information
on the assembly of the desktop detector, please see Figure S3 and Supporting Movie S2
(Supplementary Materials).
3. Results and Discussion
3.1. Design of Viral Sensitive Gold–Oligonucleotide Nanoconstructs
Gold–oligonucleotide-nanoconstructs are gold nanoparticles aggregated by oligonu-
cleotides sensitive to a target nucleic acid sequence. When oligonucleotides hybridise with
the target nucleic acid sequences, gold nanoparticles disaggregate, initiating a signal trans-
duction pathway (Figure 1), which can be characterised via colourimetric, spectroscopic,
and lateral flow assays. Gold–oligonucleotide nanoconstructs sensitive to enteroviral nu-
cleic acids were fabricated via a systematic methodology, which included identification of
target nucleic acid and in silico oligonucleotide design, synthesis of gold nanoparticles and
functionalisation of their surfaces, and characterisation of the signal transduction pathway.
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Figure 1. Diagrammatic representation of signal transduction mechanisms of gold–oligonucleotide nanoconstructs using
(A) colourimetric response and (B) differential binding. (Ai) Oligonucleotide 5′ GA AAC ACG GAC ACC CAA AGT AGT
3′ aggregates nanoparticles functionalised with Sequence A (SH-5′ A12 CCC AGG ACT AC T TTC 3′) and Sequence B
(Biotin—5′ GTG TTT CGG GAA G 3′—SH). (Aii) Target nucleic acid hybridises with oligonucleotide and (Aiii) disaggregates
gold nanoparticles to produce a visual and spectroscopic colour change from purple to deep red. (Bi) Aggregated particles
do not move upon lateral flow in the absence of target nucleic acid. However, in the presence of (Bii) target nucleic
acid, gold particles are disaggregated and able to flow on lateral flow membranes and bind streptavidin because of
biotin functionalisation.
Sequences for the enterovirus genus were identified using the National Center for
Biotechnology Information’s (NCBI’s) “Taxonomy Browser” database. Archetypal repre-
sentative strains, exclusive to human reference sequences in the enterovirus genus, were
selected and aligned using multiple sequence comparison by log-expectation (MUSCLE),
which is available in the open-source Molecular Evolutionary Genetics Analysis (MEGA)
software. The longest uniformly conserved nucleotide base sequence amongst reference
isolates returned was 23 base pairs—5′ ACU UUG GGU GUC CGU GUU UC 3′—which
resides in the 5′ non-coding region of the enteroviral genome [50] and therefore will
not produce proteins. However, this conserved nucleotide base sequence is in the stem-
loop V of the internal ribosome entry site (IRES) [51], binding the single polypyrimidine
tract-binding protein. Therefore, depending on sample composition and conditions, a
hybridization-based biosensor may be affected by the presence of competing RNA and
proteins in real-world settings. The presence of the IRES also suggests that the site is
accessible by larger molecular structures, suggesting that there could potentially be an op-
portunity for the biosensor proposed in this manuscript to detect the conserved nucleotide
sequence. For context and the purpose of the experiments detailed in this manuscript, it
is also important to note that competing molecules did not affect the performance of the
proof-of-concepts studies in this manuscript; however, competing human DNA will be
evaluated as part of cross-sensitivity/selectivity analysis in Section 3.4.
NCBI’s basic local alignment search tool (BLAST) highlighted that this sequence was
exclusive to the enteroviral genus species and had 100% identity matches with 8291/8648
(96%) sequences. This sequence has also been highlighted in the literature for its utility in
PCR priming at a serotypic level [52,53], but not at a universal genus level. Searches of
human genomic databases highlighted that the longest sequence matching human DNA
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was 17 bases on chromosome 12 (GRCh38.p13, 17/23 bases, 74% sequence identity) [54].
This could potentially be a limitation of the biosensor and could produce false positive
results; therefore, cross-sensitivity analyses were conducted. Nevertheless, these 23 bases
were selected as a target from which a bespoke oligonucleotide sequence was designed.
For the signal transduction pathway to function in the absence of the target nucleic
acid sequences, oligonucleotides should aggregate gold nanoparticles. However, in their
presence, oligonucleotides must hybridise with target nucleic acid sequences and dissociate
from gold nanoparticles, which in turn triggers their disaggregation. This was achieved by
designing an oligonucleotide that demonstrates a strong affinity for the target nucleic acid
sequence, whilst demonstrating partial affinity for nucleotides linked to the surface of gold
nanoparticles, which were used to facilitate their aggregation. Therefore, nucleotide bases
specific and complementary to the target nucleic acid were selected for the oligonucleotide
sequence 5′ GA AAC ACG GAC ACC CAA AGT AGT 3′ (Figure 1(Ai)).
This oligonucleotide was used to bridge and aggregate gold nanoparticles by partially
hybridising two different nucleotide sequences, Sequence-A (SH-5′ A12 CCC AGG ACT AC T
TTC 3′) and Sequence-B (Biotin-5′ GTG TTT CGG GAA G 3′-SH), which were linked to gold
nanoparticle surfaces via stable thiol-gold bonds [55] (Figure 1(Aii)). Sequence-A consisted of
thiol functionalisation at 5′ to bind gold nanoparticle surfaces, a polyadenylated tail (n = 12)
to minimise the interaction with signal transduction components, and 9 nucleotide bases
complementary to the 3′ oligonucleotide strand. By contrast, Sequence-B was composed of
thiol functionalisation at 3′ to bind to gold nanoparticle surfaces and 7 nucleotide bases
complementary to the 5′ oligonucleotide strand. The lateral flow device was engineered by
biotinylating Sequence-B at 5′ (Figure 1(Aiii)) such that it could be trapped by streptavidin-
functionalised membranes (Figure 1(Bi,Bii)).
Assembly of gold–oligonucleotide nanoconstructs via this partial nucleic acid com-
plementation method consigns 7 nucleotide bases (5′ G GAC ACC 3′) at the centre of
the oligonucleotide as unbound. This ensures that the oligonucleotide will preferen-
tially hybridise with the conserved target enteroviral nucleic acid sequence, thus al-
lowing gold nanoparticles to disaggregate and initiate the signal transduction pathway
(Figure 1(Aii,Aiii)).
3.2. Synthesis and Characterisation of Gold–Oligonucleotide Nanoconstructs Sensitive to
Conserved Target Enteroviral Nucleic Acid Sequences
The spectroscopic (colour and ultraviolet UV absorbance maxima) and physicochemi-
cal properties (mobility across lateral flow membranes) of gold nanoparticles differ when
they are in disaggregated or aggregated constructs. Therefore, prior to harnessing these
properties to develop a biosensor to detect conserved target enteroviral nucleic acid se-
quences, gold nanoparticles and gold–oligonucleotide nanoconstructs were synthesised,
functionalised with Sequence-A, Sequence-B and oligonucleotide, and characterised for their
spectroscopic properties, size, and zeta potential.
Colloidally stable gold nanoparticles were synthesised via sodium citrate reduction.
Disaggregated gold nanoparticles exhibit a characteristic deep red colour with a UV absorp-
tion maximum at 524 nm (Figure S4). Aggregation of citrate-stabilised gold nanoparticles
with a concentrated salt solution red-shifts the wavelength of their absorbance maxima to
544 nm and their appearance to a dark purple colour (Figure S4). Functionalisation of gold
nanoparticle surfaces with Sequence-A and Sequence-B was performed by independently
reducing the thiol groups on the nucleic acid sequences in the presence of gold nanopar-
ticle suspensions. Gold–oligonucleotide nanoconstructs were assembled by incubating
gold nanoparticles functionalised with Sequence-A and Sequence-B in a 1:1 ratio, with an
initial molar excess of the oligonucleotide strand, overnight. Unbound oligonucleotides
and disaggregated gold nanoparticles were removed with washing and centrifugation to
produce gold–oligonucleotide nanoconstructs aggregated suspended in a buffer solution
composed of sodium chloride (600 mM) and tris acetate (25 mM).
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DLS was used to record the mean-centred hydrodynamic diameters for unfunction-
alised gold nanoparticles (13 nm diameter, 0.50 PDI), Sequence-A- (17 nm diameter, 0.12 PDI)
and Sequence-B (12 nm diameter, 0.14 PDI)-functionalised gold nanoparticles, and gold–
oligonucleotide nanoconstructs (1154 nm diameter, 0.36 PDI) (Figure 2A). Unfunctionalised
nanoparticles and Sequence-A- and Sequence-B-functionalised gold nanoparticles exhib-
ited comparable particle size distributions. The subtle changes in mean hydrodynamic
diameter observed by DLS could be attributed to differences in gold nanoparticle bound
nucleic acid chain composition, length, and corresponding ionisation (Figure 1, Sequence-A
8442.7 Mw, Sequence-B 4241.9 Mw, and Sequence-B-Biotin 4811.5 Mw). However, when
Sequence-A- and Sequence-B-functionalised gold nanoparticles were aggregated with the
sense oligonucleotide, the mean-centred hydrodynamic diameter, as measured with DLS,
was considerably larger (50×), which, alongside colourimetric and spectroscopic char-
acterisation, confirmed that gold–oligonucleotide nanoconstructs were fabricated. The
relatively large particle size distribution associated with gold–oligonucleotide nanocon-
structs suggests that there is heterogeneity during aggregate production, such that their
hydrodynamic architecture can span greater than 1 µm in diameter.
Figure 2. (A) Dynamic light scattering-measured mean-centred particle size distribution and (B) zeta potential measurements
for unfunctionalised gold nanoparticles (Gold–Blank), gold nanoparticles functionalised with Sequence–A (Gold–Seq–A) and
Sequence-B (Gold–Seq–B), and gold–oligonucleotide nanoconstructs (Gold–Constructs). TEM images for (C) unfunctionalised
gold nanoparticles and (D) gold–oligonucleotide nanoconstructs. Scale bar = 100 nm.
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The binding of thiolated nucleotide sequences to the surface of gold nanoparticles
was confirmed by determining their zeta potential (Figure 2B). Unfunctionalised gold
nanoparticles, Sequence-A- and Sequence-B-functionalised gold nanoparticles, and aggre-
gated nanoparticles exhibited zeta potentials of −21.9 ± 5.21 mV, −15.37 ± 3.23 mV and
−20.77 ± 2.95 mV, and −17.8 ± 0.95 mV, respectively. These results suggest that function-
alised nanoparticle surfaces exhibit a marginal increase in zeta potential, although not sig-
nificant (p > 0.01), when compared with unfunctionalised nanoparticles. Furthermore, the
aggregates, which are formed from a construct of Sequence-A- and Sequence-B-functionalised
gold nanoparticles, as expected, exhibited a zeta potential between the zeta potentials of
Sequence-A- and Sequence-B-functionalised gold nanoparticles.
TEM was used to characterise the size of unfunctionalised and functionalised gold
nanoparticles, as well as to determine the distribution of disaggregated unfunctionalised
gold nanoparticles and gold–oligonucleotide nanoconstructs. The diameter of unfunction-
alized nanoparticles was centred at 13± 1.71 nm (n = 50, Figure 2C and Figure S5). The size
of unfunctionalised and gold nanoparticles functionalised with Sequence-A and Sequence-B
was indistinguishable when imaged using TEM (Figure 2 and Figure S6). This observation
could be due to the apparent sizes of Sequence-A and Sequence-B and the resolution power of
the TEM. For example, nucleic acid sequences that are 10 base pairs long are approximately
34 Å (0.34 nm) in length. Therefore, gold nanoparticles functionalised with Sequence-A
(27 nucleotide bases, 0.918 nm) and Sequence-B (13 nucleotide bases, 0.44 nm) would be
extremely challenging to differentiate, as the size of the nucleotide sequences falls within
the error for unfunctionalised nanoparticles size measurement.
Unfunctionalised gold nanoparticles, when imaged using TEM, were dispersed, ap-
pearing as individual nanoparticles or in small clusters (<10 gold nanoparticles) (Figure 2C).
In comparison, gold–oligonucleotide nanoconstructs were composed of large nanoparticle
complexes (>50 gold nanoparticles) (Figure 2D). The distribution of unfunctionalised gold
nanoparticles and gold–oligonucleotide nanoconstructs and the interaction of light with
the surface plasmon on free and aggregated nanoparticles could be attributed to the ob-
served visual and spectral differences [56]. Dispersed gold nanoparticles absorb and reflect
light at ~500 nm and ~700 nm, respectively, producing a deep red colour. By contrast,
gold–oligonucleotide nanoconstructs behave similarly to larger gold nanoparticles, and
the surface plasmon resonance absorption wavelength is shifted, such that red light is
absorbed, and blue light is reflected, producing a purple colour. These observed visual
and spectral differences between disaggregated nanoparticles and gold–oligonucleotide
nanoconstructs were used as a signal transduction mechanism to detect conserved target
enteroviral nucleic acid sequences.
3.3. Detecting Conserved Target Enteroviral Nucleic Acid Sequences with Gold–Oligonucleotide
Nanoconstructs
The sensitivity of gold–oligonucleotide nanoconstructs was assessed by challenging
the assay to conserved enteroviral sequence containing thymine (or 5-methyuracil, T)
(5′ACT ACT TTG GGT GTC CGT GTT TC 3′). Uracil (U) and 5-methyuracil are nucleotide
bases that are found in RNA and DNA, respectively, and form hydrogen-bonded base pairs
with adenine (A). The A–U hydrogen bond is stronger than the A–T hydrogen bond [57],
therefore our reported sensitives are likely to underestimate the ultimate limit of detection.
The signal transduction mechanism was investigated using (1) spectroscopy, through
observation of the changes in absorbance intensity and the shift in absorbance maxima;
(2) visually inspecting the colour changes of aggregates; and (3) application of lateral
flow assays.
Spectroscopic analysis of the absorbance response of the gold–oligonucleotide
nanoconstructs to log dilutions of target enteroviral nucleic acid, from 1 × 10−4 M to
1 × 10−11 M, showed that there was a decrease in absorbance amplitude and a blue shift in
the absorbance wavelength maxima (Figure 3A). The response of the gold–oligonucleotide
nanoconstructs was sigmoidal, without an apparent maximum, because of the finite num-
ber of oligonucleotide-based sensing elements that lead to initiation of a signal trans-
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duction cascade in the presence of conserved target enteroviral nucleic acid sequences.
The absorption maxima intensity of gold–oligonucleotide nanoconstructs at 524 nm were
significantly increased in the presence of target enteroviral nucleic acids ≥1 × 10−7 M
(≥6.02 × 10−13 copies/mL,≥13 log10 copies/mL,≥1.4× 10−14 g/mL, p < 0.01; Figure 3B).
A detection limit of≥1× 10−7 M is equivalent to >6.021016 viral particles, when Avogadro’s
constant is 6.02 × 1023 mol−1, and estimating that each viral particle consists of a single
copy of the target nucleic acid sequence. It is important to note the data represented in
Figure 3B are a true representation of the real-world use of gold–oligonucleotide nanocon-
structs. Gold–oligonucleotide nanoconstructs consist of delicate structures that vary from
batch to batch and exhibit an absorbance difference. Furthermore, this does not significantly
affect their ability to make measurements of target enteroviral nucleic acid ≥1 × 10−7 M
(p < 0.01). These findings were mirrored for the wavelength shift of gold–oligonucleotide
nanoconstructs to changes in target enteroviral nucleic acid (Figure 3C), such that shifts in
peak absorbance wavelength were also observed at ≥1 × 10−7 M (Figure 3D).
Spectroscopic shifts in wavelength of gold–oligonucleotide nanoconstructs to the
conserved target enteroviral nucleic acid were also visually observed for conserved target
enteroviral nucleic acid concentrations ≥1 × 10−6 M, which is above the detection limit
of spectroscopy (≥1 × 10−7 M). This difference can be attributed to both the enhanced
sensitivity of spectroscopy as a detection technique and the limitations of the human eye
to determine subtle changes in absorbance and the submaximal spectroscopic response in
absorbance and wavelength shift at≥1× 10−7 M [58]. Therefore, to produce an economical
detection technique that is independent of spectroscopy but demonstrates comparable
sensitivity, lateral flow assays were investigated.
When gold–oligonucleotide nanoconstructs disaggregate in the presence of the target
nucleic acid, they exhibit enhanced flow properties on lateral flow membranes because of
a reduction in their physical size (Figure 2C,D). Therefore, free gold nanoparticles func-
tionalised with Sequence-B, which contain biotin, were shown to bind streptavidin-doped
lateral flow membranes at predetermined sites via one of the strongest non-covalent in-
teractions found in nature [59]. The lateral flow device was able to detect levels of the
target viral nucleic acid of ≥1 × 10−7 M (Figure 3F). This sensitivity is comparable to the
detection limit of the spectroscopic measurement and outperforms visual inspection of the
colour change alone. The observed detection limits for the gold–oligonucleotide nanocon-
structs were comparable to previously reported gold nanoparticle-based detection systems
that have been used for laboratory identification of viruses [60]. Clinically, enteroviral
loads are typically acquired from nasal swabs and their concentrations are recorded as
log10 copies/mL using PCR [61]. Therefore, the detection limit of gold–oligonucleotide
nanoconstructs (13 log10 copies/mL) would fall outside of the nasal swab based clinically
recorded relevant range (5.3 (±1.5)–6.4 (±1.3) log10 copies/mL) [62]. It is important to note
that our detection limit was determined without any amplification of viral nucleic acid.
The difference in detection limit could be overcome through alternate sample collection
methods (throat swabs) as well as concentrating viral load through method optimisation,
such as the addition of virus isolation and purification steps.
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Figure 3. Response of gold–oligonucleotide nanoconstructs to conserved target enteroviral nucleic acid sequence, with
concentrations ranging from 1× 10−4 M to 1× 10−11 M, recorded as changes in (A,B) absorbance intensity, (C,D) wavelength
redshift, (E) optical colour change, and (F) lateral flow assay, with region of interest highlighted with red dotted line,
indicating detection of target nucleic acid sequence. Please note that the light band positioned at the centre of the lateral
flow device indicates location of streptavidin deposition. Calibration curves show changes in (B) absorbance maxima with
subtraction of background absorbance, and (D) wavelength (n = 3, where error is standard deviation and ** p < 0.01).
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3.4. Cross-Sensitivity/Selectivity Analyses
It is anticipated that non-invasive throat swabs, which contain a high number of
viral particles during an infection [63], will be utilised when stratifying individuals that
are positive or negative for target enteroviral nucleic acid using gold–oligonucleotide
nanoconstructs. Therefore, to determine the applicability of the gold–oligonucleotide
nanoconstructs in the real-world scenario of a typical doctor–patient consultation, pre-
liminary experiments were conducted to determine the lateral flow assay efficacy at its
detection limit (~1 × 10−7 M) with equivalent mass concentrations of human genomic
DNA (~3.2 g/L, ~6.15 × 10−12 M). It is important to note that the molar concentration
of human genomic DNA in this experiment was ~10,000× less than that of the target
enteroviral nucleic acid, as viral infection of a cell can produce up to 10,000 new viral
particles [64]. In the absence of conserved target enteroviral nucleic acid, the assay was
negative since human genomic DNA does not initiate the signal transduction pathway
(Figure S7). Furthermore, in the presence of conserved target enteroviral nucleic acid, the
human genomic DNA did not affect the sensitivity of the lateral flow assay.
The time to detection of the lateral flow assay was also evaluated to determine its
utility in clinical settings. This was conducted by monitoring the duration of time taken
for the lateral flow assay to produce a detection band at a predetermined streptavidin
region of interest. Using our experimental setup, a detection band was observed in <60 s
(Supporting Movie S1 (Supplementary Materials)).
Furthermore, to establish an unambiguous interpretation of the gold–oligonucleotide
nanoconstruct-based lateral flow assay, which could be used by both healthcare profession-
als and patients, a bespoke software and hardware solution was engineered. The desktop
detector was composed of a light-emitting diode (LED) and LDR, positioned perpendicular
to a printed circuit board and separated by an opaque light barrier (Figure 4). The light
barrier only permits reflected light to be sensed by the LDR; therefore, in the presence of
an enteroviral positive lateral flow membrane (Figure 4(Ai)), compared with an enteroviral
negative membrane (Figure 4(Aii)), relatively less light was reflected and consequentially
sensed by the LDR. The difference in light reflectance corresponded to a change in electrical
resistance. A central processing unit was programmed to threshold the change electrical
resistance, such that a user interface instantly displayed “NEGATIVE” (Figure 4(Bi)) or
“POSITIVE” (Figure 4(Bii)) in the presence or absence of the conserved enteroviral nucleic
acid (Supporting Movie S2). Based on our understanding of sample acquisition time
(<1 min), preparation time (<2 min), and implementation of the lateral flow assay and
desktop detector (<1 min) we anticipate that the total time required to complete an analysis
would be ~5 min. This is well within the time frame of a typical doctor–patient consultation
(~10 min), providing sufficient time for a thorough clinical evaluation [65] prior to the
implementation of a gold–oligonucleotide nanoconstruct enteroviral assay.
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Figure 4. (A) Diagrammatic representation and (B) photographs of desktop detector response to (Ai,Bi) negative and
(Aii,Bii) positive conserved target enteroviral nucleic acid sequence lateral flow assay. For further information see Figure S3
and Supporting Movie S2 (Supplementary Materials).
4. Conclusions
Gold–oligonucleotide nanoconstructs sensitive to a target enteroviral nucleic acid
sequence conserved amongst 96% of all known enteroviruses were fabricated. Oligonu-
cleotides were designed in silico to fully complement the target enteroviral nucleic acid
and partially hybridise with gold nanoparticles functionalised with complementary nucleic
acid. In silico design provides a flexible platform that can be readily optimised to produce
multiplexed devices capable of simultaneously detecting an array of analytes. For example,
gold–oligonucleotide nanoconstructs could be multiplexed to simultaneously stratify pa-
tients presenting with symptoms of viral, bacterial, and mixed viral/ bacterial infections.
Furthermore, in the context of the COVID-19 pandemic [66], gold–oligonucleotide nanocon-
structs could also be multiplexed to detect SARS-CoV-2 variants [67] or additional viruses
(e.g., influenza), which could be used to inform effective use of preventative medicines [68]
or treatment pathways [69].
In the presence of the conserved target enteroviral nucleic acid sequence, a signal trans-
duction mechanism was initiated, and gold–oligonucleotide nanoconstructs disaggregated.
Multimodal colourimetric (purple to red), spectroscopic (544 nm to 524 nm), and lateral flow
assays (binding of biotin functionalised gold nanoparticles to streptavidin-doped mem-
branes) were shown to be sensitive towards the target nucleic acid sequence ≥1 × 10−7 M
(≥1.4 × 10−14 g/mL). This multimodal approach could be used as a powerful control to
triangulate the detection of a target nucleic acid sequence between methodologies and pro-
vide a summative method for sample negative/positive identification. Future studies will
develop negative controls for the lateral flow assay, which could serve as an independent
tool for the confirmation or absence of the target nucleic acid sequence.
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Lateral flow assays were unaffected by contaminating human DNA, and a complete
analysis from sample acquisition to detection could potentially take <5 min. It is also
important to note that the reagents, including oligonucleotides, and the electronic compo-
nents used to prepare the gold–oligonucleotide nanoconstructs and the desktop detector
are widely available. Therefore, if mass-produced in comparable economies of scale to
the antibody-based pregnancy test, we hypothesise that a fully functioning biosensor
could potentially be manufactured for ~10 USD, where the lateral flow device and desktop
diagnostics could be produced for <1 USD and <10 USD, respectively.
The research demonstrated in this article indicates that these detection modalities are
extremely practical; however, at present lack the required sensitivity to be clinically relevant.
The detection sensitivities could be considerably enhanced through the implementation
of improved oligonucleotides demonstrating greater specificity for enterovirus structures,
such as those for the viral capsid [38]. We anticipate our economical, simple, and rapid
assay could be translated into an accessible point-of-care desktop detector device through
optimisation of sample preparation, improvements in the detection limit, and evaluation
with clinically relevant samples, which include enterovirus, influenza and coronavirus,
and other infectious agents. Ultimately, our approach could pave the way forward in the
simultaneous detection of multiple viruses and complement existing strategies aimed at
overcoming antimicrobial resistance.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/bios11070238/s1, Additional content includes Supporting Information PDF. Figure S1. Lat-
eral flow device (A) diagrammatic and (B) actual device representation. Figure S2. Production of
lateral flow device using (A) absorption pads, sample pads, lateral flow membranes, and (B) lami-
nated backing paper. Lateral flow devices produced (C) individually and (D) in a high-throughput
batch format. Scale bars = 5 cm. Figure S3. (A) Top and (B) cross-sectional view of LED, Light
Barrier, and LDR positioning. (C) Internal specification (STM board, LCD display, light-emitting
diode (LED) and LDR) and (D) external profile (desktop diagnostic (with later flow cartridge insert),
positive (left) and negative cartridges (right) and power outlet). See Supporting Movie S2 for desk-
top diagnostic operation. Figure S4. Absorbance spectra for disaggregated and aggregated gold
nanoparticles. Absorbance maxima for free and aggregated nanoparticles were 524 nm and 544 nm,
respectively. Inset image of disaggregated (left) and aggregated (right) gold nanoparticle suspensions.
Figure S5. Histogram of unfunctionalized gold nanoparticle size distribution determined from
TEM (n = 50). Figure S6. TEM images for gold nanoparticles functionalised with (A) Sequence-A,
(B) Sequence-B, and (C) after signal transduction pathway has been initiated following addition of
conserved target enteroviral nucleic acid sequence. Scale bars = 100 nm. Figure S7. Response of
gold–oligonucleotide nanoconstructs to target viral DNA in the presence of human genomic DNA
(0.1 µM), with (A) colourimetric change and (B) lateral flow assay. (C) Summary of lateral flow
findings showing that signal transduction mechanism of gold–oligonucleotide nanoconstructs is
not initiated in the presence of human genomic DNA (H-DNA, 0.1 µM) and does not affect the
triggering of signal transduction cascade for the conserved target enteroviral nucleic acid (CTENA,
0.1 µM). Supporting Movie S1. Rapid colourimetric response of gold–oligonucleotide nanoconstructs
in suspension when challenged with conserved target enteroviral nucleic acid (0.1 µM) and the
binding of disaggregated biotin-functionalised gold nanoparticles to streptavidin of lateral flow
assays. Supporting Movie S2. Differentiation of conserved target enteroviral nucleic acid positive
and negative lateral flow cartridges using custom-designed diagnostic.
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